Enlivex Ltd.
ENLV
Positions held
Your positionsENLV isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $5.51M | Enterprise value | $16.69M | Trailing P/E | 0.00 | Forward P/E | -0.36 |
| PEG | — | Price / book | 0.00 | Beta | 1.41 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | 1.6% | ROA | -0.6% | Debt / equity | 0.00 |
| Current ratio | 119.39 | Free cash flow | -$3.74B | Analyst recommendation | none | Mean target | $80.00 |
| 52w high | $27.15 | 52w low | $0.26 |
Quarterly
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | $1.2B | -$2.2M | -$1.9M | -$3.5M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$5.9M | -$2.6M | -$3.1M | -$3.5M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | $1.2B | -$15.0M | -$29.1M | -$31.1M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$15.0M | -$14.9M | -$25.2M | -$25.8M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-01 · Enlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
2026-07-28 · Enlivex Shares Plunge After $400 Million Private Placement Deal
2026-07-28 · Top Midday Decliners
2026-07-13 · Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why
2026-07-13 · Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-07-13 · Enlivex's Allocetra Receives FDA RMAT Designation for Knee Osteoarthritis
2026-07-13 · Exclusive: FDA grants RMAT designation to Enlivex’s Allocetra for knee OA
Price (daily)
Full chart · RSI · MACD · patterns